跳至主要内容
临床试验/JPRN-UMIN000050760
JPRN-UMIN000050760
已完成
未知

A cross-sectional, web-based survey of physicians in breast cancer treatment to reveal the underserved patient population who do not receive CDK4/6 inhibitor plus endocrine therapy and to identify the challenges of the disparity in Japan - A cross-sectional, web-based survey of physicians in breast cancer treatment to reveal the underserved patient population who do not receive CDK4/6 inhibitor plus endocrine therapy and to identify the challenges of the disparity in Japan

Pfizer Japan Inc.0 个研究点目标入组 300 人2023年4月10日

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
HR+/HER2- advanced breast cancer
发起方
Pfizer Japan Inc.
入组人数
300
状态
已完成
最后更新
2年前